Becton, Dickinson and Company (BDX) Position Cut by Wimmer Associates 1 LLC

Wimmer Associates 1 LLC cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,824 shares of the medical instruments supplier’s stock after selling 350 shares during the period. Becton, Dickinson and accounts for 2.3% of Wimmer Associates 1 LLC’s holdings, making the stock its 7th biggest position. Wimmer Associates 1 LLC’s holdings in Becton, Dickinson and were worth $2,513,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and in the first quarter worth about $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the last quarter. Parkside Financial Bank & Trust increased its position in Becton, Dickinson and by 8.1% during the second quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 51 shares during the last quarter. Harfst & Associates Inc. increased its position in Becton, Dickinson and by 46.4% during the second quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd increased its position in Becton, Dickinson and by 82.8% during the second quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after purchasing an additional 338 shares during the last quarter. 88.46% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently weighed in on BDX shares. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Royal Bank Of Canada restated a “hold” rating and issued a $210.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Tuesday, October 31st. Cowen restated a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays restated an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Becton, Dickinson and has a consensus rating of “Buy” and a consensus price target of $217.08.

In other news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now directly owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) opened at $218.92 on Thursday. The firm has a market cap of $49,943.21, a P/E ratio of 23.08, a PEG ratio of 1.72 and a beta of 1.07. The company has a current ratio of 5.58, a quick ratio of 5.03 and a debt-to-equity ratio of 1.44. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $229.68.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the consensus estimate of $2.37 by $0.03. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.12 EPS. research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date is Thursday, December 7th. Becton, Dickinson and’s payout ratio is presently 62.80%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.com-unik.info/2017/12/07/becton-dickinson-and-company-bdx-position-cut-by-wimmer-associates-1-llc.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit